

#### **SUPPLEMENTAL EXAMINER'S AMENDMENT**

1. This supplemental amendment corrects a typographical error on the examiner's amendment mailed 25 November 2009. The words "claim 71, line 5", appearing at the beginning of the final paragraph on p. 2 of that amendment, should read "claim 74, line 5". The present amendment merely corrects that error.
2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Rosemarie Celli on 14 December 2009.

3. The application has been amended as follows:

Claim 71 now reads as follows:

A method of reducing the risk, lessening the severity, or delaying the outset of disease in a patient having a known genetic risk of Parkinson's disease, the method comprising administering to the patient an effective regime of an agent and thereby reducing the risk, lessening the severity or delaying the outset of the disease;  
wherein (i) the agent is A $\beta$  or an immunogenic fragment thereof, and the agent is linked to a carrier that helps elicit an immune response to the agent or is administered with an adjuvant that augments an immune response to the agent, or (ii) the agent is an antibody to A $\beta$ .

Claim 74 now reads as follows:

A method of reducing the risk, lessening the severity, or delaying the outset of disease in a patient having a known genetic risk of Parkinson's disease, the method comprising administering to the patient an effective regime of a first agent and a second agent that induces an immunogenic response against A $\beta$  in the patient and thereby reducing the risk, lessening the severity or delaying the outset of the disease;  
wherein (i) the first agent is alpha synuclein or an immunogenic fragment thereof and the first agent is linked to a carrier that helps elicit an immune response to the first agent or is

Art Unit: 1649

administered with an adjuvant that augments an immune response to the first agent, or (ii) the first agent is an antibody to alpha synuclein, and

wherein (i) the second agent is A $\beta$  or an immunogenic fragment thereof, and the second agent is linked to a carrier that helps elicit an immune response to the second agent or is administered with an adjuvant that augments an immune response to the second agent, or (ii) the second agent is an antibody to A $\beta$ .

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL KOLKER whose telephone number is (571)272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Daniel E. Kolker/

Primary Examiner, Art Unit 1649

December 14, 2009